이 페이지는 자동 번역되었으며 번역의 정확성을 보장하지 않습니다. 참조하십시오 영문판 원본 텍스트의 경우.

중등도 알츠하이머병 참가자를 대상으로 한 SNK01의 I/IIa 단계 연구

2026년 9월 29일 업데이트: NKGen Biotech, Inc.

중등도 알츠하이머병 참가자를 대상으로 SNK01의 안전성, 내약성 및 탐색적 효능을 평가하기 위한 I/IIa상 연구

The goal of this clinical trial is to test SNK01 in participants with moderate Alzheimer's Disease. The main questions it aims to answer are:

  1. Is SNK01 safe and tolerable when administered every 3 weeks for up to 1 year as an intravenous infusion
  2. Can SNK01 administration improve cognitive assessment scores and biomarkers

연구 개요

상태

모병

정황

개입 / 치료

연구 유형

중재적

등록 (추정된)

36

단계

  • 2 단계
  • 1단계

연락처 및 위치

이 섹션에서는 연구를 수행하는 사람들의 연락처 정보와 이 연구가 수행되는 장소에 대한 정보를 제공합니다.

연구 연락처

연구 장소

    • California
      • Glendale, California, 미국, 91206
        • 모병
        • Behavioral Research Specialists, LLC
        • 연락하다:
      • Santa Ana, California, 미국, 92705
        • 모병
        • Syrentis Clinical Research
        • 연락하다:
      • Tarzana, California, 미국, 91356
        • 빼는
        • Valiance Clinical Research
    • Florida
      • Maitland, Florida, 미국, 32751
      • Orlando, Florida, 미국, 32804
    • New Jersey
      • Newark, New Jersey, 미국, 07107
    • New York
      • Albany, New York, 미국, 12208
        • 모병
        • Alzheimer's Disease Research Center
        • 연락하다:
    • Ontario
      • Ottawa, Ontario, 캐나다, K1Z 1G3
        • 빼는
        • Ottawa Memory Clinic

참여기준

연구원은 적격성 기준이라는 특정 설명에 맞는 사람을 찾습니다. 이러한 기준의 몇 가지 예는 개인의 일반적인 건강 상태 또는 이전 치료입니다.

자격 기준

공부할 수 있는 나이

40년 (성인, 고령자)

건강한 자원 봉사자를 받아들입니다

아니

연구 대상 성별

모두

설명

Inclusion Criteria:

  1. The participant or their legally authorized representative must be willing and able to give their informed consent in writing and comply with the requirements of this study protocol. Informed consent for participants or their legally authorized representative and caregivers will be obtained before any trial-related activity. (Trial-related activities are any procedure that would not be performed during normal treatment of the participant).

  2. Participants must have a reliable study partner/caregiver (per investigator judgement for instance a family member, partner etc., guardian (must be always the same person)) who is in close contact with the patient, available on call and who is able to contribute to the assessment of the ratings of the functional endpoints at specific study visits. This person will be able to communicate in the language in which the participant is being assessed and should also serve as a backup contact for the study site. The study partner/caregiver must sign a separate informed consent form which describes their contributions during the study.

  3. Patients with diagnosis of Alzheimer's dementia according to the recommendations from the 2011 National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease.

  4. Age 40 to 85 years old.

  5. Patients must have at least 6 years of formal education and fluency in the test language as verbally confirmed by the patient or their legally authorized representative and documented by the study investigator.

  6. Female participants of childbearing potential must have a negative urine pregnancy test at Screening and Visit 1 before first administration of the study drug. Females of childbearing potential are defined as those who are not surgically sterile or who are not post-menopausal (i.e.: no menses for at least 1 year). Male and female participants of reproductive potential must also agree to abstinence or use acceptable form(s) of effective contraception during the study and for 30 days after the final dose of the study drug. Acceptable methods of contraception include the following:

    1. Condoms, sponges, foams, gels, diaphragms, or intrauterine device (IUD).
    2. Hormonal birth control for 30 days prior to administration of the study drug.
    3. A vasectomized sexual partner.
  7. Positive evidence for a diagnosis of AD via amyloid positron emission tomography (Amyloid PET) of the brain within the past six months.

  8. CDR-SB score of ≥ 9.5 and <16.0.

Exclusion Criteria:

  1. Substantial concomitant cerebrovascular disease defined as Fazekas Grade 3.
  2. History of a stroke/intracranial hemorrhage temporally related to the onset of worsening of cognitive impairment in the opinion of the investigator.
  3. Any substance use disorder that has not been in remission for at least 12 months
  4. Medical history of cancer (except for basal cell carcinoma) and/or treatment for cancer within the last 5 years.
  5. Uncontrolled cardiovascular illnesses such as chronic congestive heart failure (with or without oedema), tachycardia, arrhythmias, uncontrolled hypertension.
  6. History of cerebrovascular accident or transient ischemic attack (TIA), or unexplainable loss of consciousness within the last year.
  7. Significant pulmonary disease predisposing to hypoxia.
  8. Significant ischemic heart disease, myocardial infarction within the last two years and/or with residual angina, orthopnea, conduction defects (ECG), or any other clinically significant heart disease classified as NYHA III or IV.
  9. Significant liver disease (for example cirrhosis, active hepatitis B and C, primary or metastatic liver neoplasm).
  10. Indication of liver disease, defined by serum levels of either ALT (SGPT), AST (SGOT), or alkaline phosphatase above 3 x upper limit of normal (ULN) as determined during screening.
  11. Significant gastrointestinal disorders (for example gastrointestinal bleeding within the last two years, malabsorption syndromes, post-gastrectomy, or active peptic ulcer disease).
  12. Immunological disorder such as per investigator judgement clinically significant allergies, Lupus erythematodes, or scleroderma.
  13. Uncontrolled/Unstable hematological disease (regardless of cause) such as refractory anemia or refractory myelosuppression.
  14. Neurological disease (such as: Lewy body dementia - primary diagnosis, Huntington's disease, Parkinson's Disease, encephalitis, epilepsy, vascular or multi-infarct dementia, stroke, congenital mental deficiency, multiple sclerosis) and psychiatric disorders (such as schizophrenia, or intellectual disability), or any other disorders impacting cognitive function.
  15. Unstable/uncontrolled major depression or anxiety within the last 12 months.
  16. History of seizures in the past three years.
  17. Uncontrolled endocrine disease such as uncontrolled diabetes mellitus or manifest hyperthyroidism, in the opinion of the investigator.
  18. Severe renal impairment defined as a GFR < 30 mL/min/1.73 m2 in the screening lab report
  19. Infection with human immunodeficiency virus (HIV), hepatitis B, hepatitis C, or any other infection or active systemic disease.
  20. Currently being treated with anticoagulants (except aspirin at or below a prophylactic dose).
  21. Participants who are taking medications for AD, like memantine or acetylcholinesterase inhibitors (AChEI) that exceeds the normal recommended dose range or have not achieved a stable dose for the 30 days prior to enrollment.
  22. Any contraindication for performing a brain MRI and/or Amyloid PET scan.
  23. Any participant whose safety the investigator considers to be at risk from this trial's intervention.
  24. Participants with any medically unstable/uncontrolled conditions.
  25. Any suicidal behavior in the past 2 years (i.e. actual attempt, interrupted attempt, aborted attempt, or preparatory acts or behavior).
  26. Any suicidal ideation of type 4 or 5 in the C-SSRS in the past 3 months (i.e. active suicidal thought with intent but without specific plan, or active suicidal thought with plan and intent).

공부 계획

이 섹션에서는 연구 설계 방법과 연구가 측정하는 내용을 포함하여 연구 계획에 대한 세부 정보를 제공합니다.

연구는 어떻게 설계됩니까?

디자인 세부사항

  • 주 목적: 치료
  • 할당: 무작위
  • 중재 모델: 순차적 할당
  • 마스킹: 네 배로

무기와 개입

참가자 그룹 / 팔
개입 / 치료
실험적: SNK01

SNK01 will be administered as an IV infusion Q3W for up to 1 year.

SNK01 is a novel cell-based, patient specific ex vivo expanded autologous natural killer (NK) cell, immunotherapeutic drug

위약 비교기: Placebo

Placebo will be administered as an IV infusion Q3W for up to 1 year.

Sodium Lactate Hartmann's Solution

연구는 무엇을 측정합니까?

주요 결과 측정

결과 측정
측정값 설명
기간
Number of participants with dose-limiting toxicity
기간: 3 weeks

DLTs will be assessed by the review of labs, PE and AEs

3 weeks
Maximum tolerated dose determination
기간: 3 weeks

Determine the maximum tolerated dose based on the evaluation of the number of participants who experience a DLT which will then determine the RP2D.

3 weeks
Number of participants with treatment-related adverse events as assessed by CTCAE v5.0
기간: 1 Year

Evaluate the safety and tolerability of SNK01 assessed by labs, PE and AEs

1 Year
Preliminary efficacy in cognitive assessment scores of CDR-SB
기간: 1 Year

Measure changes in cognitive assessment of CDR-SB from baseline

1 Year
Preliminary efficacy in cognitive assessment scores of MMSE
기간: 1 Year

Measure changes in cognitive assessment of MMSE from baseline

1 Year
Preliminary efficacy in cognitive assessment scores of NPI
기간: 1 Year

Measure changes in cognitive assessment of NPI from baseline

1 Year
Preliminary efficacy in cognitive assessment scores of ADCS-ADL-Severe
기간: 1 Year

Measure changes in cognitive assessment of ADCS-ADL-Severe from baseline

1 Year
Preliminary efficacy in cognitive assessment scores of ADAS-Cog
기간: 1 Year

Measure changes in cognitive assessment of ADAS-Cog from baseline

1 Year

2차 결과 측정

결과 측정
측정값 설명
기간
Changes in CSF biomarkers (pTau 181, Aβ42/40, GFAP, NfL)
기간: 1 Year

Measure changes in CSF biomarkers as changed from baseline

1 Year
Changes in plasma biomarkers (pTau 181, Aβ42/40, GFAP, NfL)
기간: 1 Year

Measure changes in Plasma biomarkers as changed from baseline

1 Year

공동 작업자 및 조사자

여기에서 이 연구와 관련된 사람과 조직을 찾을 수 있습니다.

스폰서

연구 기록 날짜

이 날짜는 ClinicalTrials.gov에 대한 연구 기록 및 요약 결과 제출의 진행 상황을 추적합니다. 연구 기록 및 보고된 결과는 공개 웹사이트에 게시되기 전에 특정 품질 관리 기준을 충족하는지 확인하기 위해 국립 의학 도서관(NLM)에서 검토합니다.

연구 주요 날짜

연구 시작 (실제)

2023년 11월 21일

기본 완료 (추정된)

2028년 3월 1일

연구 완료 (추정된)

2028년 6월 1일

연구 등록 날짜

최초 제출

2023년 12월 6일

QC 기준을 충족하는 최초 제출

2024년 1월 2일

처음 게시됨 (실제)

2024년 1월 5일

연구 기록 업데이트

마지막 업데이트 게시됨 (실제)

2026년 10월 2일

QC 기준을 충족하는 마지막 업데이트 제출

2026년 9월 29일

마지막으로 확인됨

2026년 9월 1일

추가 정보

이 연구와 관련된 용어

기타 연구 ID 번호

  • SNK01-AD01

개별 참가자 데이터(IPD) 계획

개별 참가자 데이터(IPD)를 공유할 계획입니까?

아니요

약물 및 장치 정보, 연구 문서

미국 FDA 규제 의약품 연구

예

미국 FDA 규제 기기 제품 연구

아니

이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .